Chronic heart failure

a disease of the brain

Ram B. Singh, Krasimira Hristova, Jan Fedacko, Galal El-Kilany, Germaine G Cornelissen-Guillaume

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.

Original languageEnglish (US)
Pages (from-to)301-307
Number of pages7
JournalHeart Failure Reviews
Volume24
Issue number2
DOIs
StatePublished - Mar 15 2019

Fingerprint

Brain Diseases
Angiotensin II
Heart Failure
Area Postrema
Norepinephrine
Baroreflex
Paraventricular Hypothalamic Nucleus
Reflexotherapy
Subfornical Organ
Angiotensin Type 1 Receptor
Nerve Endings
Angiotensin Receptor Antagonists
Sympathetic Nervous System
Angiotensins
Brain
Aldosterone
Renin
Internet
Oxidative Stress
Central Nervous System

Keywords

  • Brain-heart interactions
  • Cardiac failure
  • Hypertrophy of heart
  • Neurohumoral dysfunction

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Chronic heart failure : a disease of the brain. / Singh, Ram B.; Hristova, Krasimira; Fedacko, Jan; El-Kilany, Galal; Cornelissen-Guillaume, Germaine G.

In: Heart Failure Reviews, Vol. 24, No. 2, 15.03.2019, p. 301-307.

Research output: Contribution to journalReview article

Singh, RB, Hristova, K, Fedacko, J, El-Kilany, G & Cornelissen-Guillaume, GG 2019, 'Chronic heart failure: a disease of the brain', Heart Failure Reviews, vol. 24, no. 2, pp. 301-307. https://doi.org/10.1007/s10741-018-9747-3
Singh, Ram B. ; Hristova, Krasimira ; Fedacko, Jan ; El-Kilany, Galal ; Cornelissen-Guillaume, Germaine G. / Chronic heart failure : a disease of the brain. In: Heart Failure Reviews. 2019 ; Vol. 24, No. 2. pp. 301-307.
@article{42fc2d741967410498d25a54e14ecba1,
title = "Chronic heart failure: a disease of the brain",
abstract = "The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.",
keywords = "Brain-heart interactions, Cardiac failure, Hypertrophy of heart, Neurohumoral dysfunction",
author = "Singh, {Ram B.} and Krasimira Hristova and Jan Fedacko and Galal El-Kilany and Cornelissen-Guillaume, {Germaine G}",
year = "2019",
month = "3",
day = "15",
doi = "10.1007/s10741-018-9747-3",
language = "English (US)",
volume = "24",
pages = "301--307",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Chronic heart failure

T2 - a disease of the brain

AU - Singh, Ram B.

AU - Hristova, Krasimira

AU - Fedacko, Jan

AU - El-Kilany, Galal

AU - Cornelissen-Guillaume, Germaine G

PY - 2019/3/15

Y1 - 2019/3/15

N2 - The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.

AB - The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.

KW - Brain-heart interactions

KW - Cardiac failure

KW - Hypertrophy of heart

KW - Neurohumoral dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85055673477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055673477&partnerID=8YFLogxK

U2 - 10.1007/s10741-018-9747-3

DO - 10.1007/s10741-018-9747-3

M3 - Review article

VL - 24

SP - 301

EP - 307

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -